

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Aducanumab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID3763]

Final Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Biogen (aducanumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Alzheimer's Research UK • Alzheimer's Society • Brain and Spine Foundation • Brain Charity • Dementia Carers Count • Dementia UK • Innovations in Dementia • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder • TIDE • United Response <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Directors of Adult Social Services • British Association for Counselling and Psychotherapy • British Association for Psychopharmacology • British Association of Behavioural and Cognitive Psychotherapies • British Association of Occupational Therapists and College of Occupational Therapists • British Association of Social Workers • British Geriatrics Society • British Neuropathological Society • British Neuropsychiatry Association • British Psychoanalytic Council • British Psychological Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Alzheimer's Scotland • Alzheimer Society of Ireland • Board of Community Health Councils in Wales • British National Formulary • Care Council for Wales • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Social Care Institute for Excellence • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare Ltd (donepezil, memantine) • Accord-UK Ltd (donepezil, galantamine, memantine) • Aspire Pharma Ltd (galantamine) • Aurobindo Pharma – Milpharm Ltd (donepezil, galantamine) • Beacon Pharmaceuticals / Kent Pharma UK Ltd (rivastigmine)

Final stakeholder list for the single technology appraisal of aducanumab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID3763]

Issue date: July 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • College of Mental Health Pharmacy • Dementia Action Alliance • Health and Care Professions Council • Institute of Neurology • Mental Health Nurses Association • Primary Care and Community Neurology Society • Primary Care Mental Health Education • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Psychiatrists • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Council for Psychotherapy <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Gloucestershire CCG • NHS South Reading CCG • Welsh Government 	<ul style="list-style-type: none"> • Cipla EU Ltd (donepezil) • Dr Reddy's Laboratories (UK) Ltd (galantamine, memantine, rivastigmine) • Eisai Ltd (donepezil) • Fontus Health Ltd (galantamine) • Genus Pharmaceuticals (memantine) • Glenmark Pharmaceuticals Europe Ltd (memantine) • Healthcare Pharma Ltd (memantine) • Lundbeck Ltd (memantine) • Lupin Healthcare (UK) Ltd (memantine) • Mylan (donepezil, memantine, rivastigmine) • Novartis Pharmaceuticals UK Ltd (rivastigmine) • Ranbaxy (UK) Ltd a Sun Pharmaceutical Company (donepezil) • Rosemont Pharmaceuticals Ltd (donepezil, memantine, galantamine, rivastigmine) • Sandoz Ltd (galantamine, rivastigmine) • Takeda UK Ltd (galantamine) • Thame laboratories (galantamine) • Zentiva (galantamine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • Genomics England • Institute of Ageing and Health • Institute of Psychiatry • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research • Research Institute for the Care of Older People <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.